Navigation Links
Central European Society for Anticancer Drug Research Announces Start of Enrollment in First Randomized Trial of Pharmacokinetic-Guided Dose Adjustment of Paclitaxel in Non-Small Cell Lung Cancer
Date:4/26/2011

VIENNA and BETHLEHEM, Pa., April 26, 2011 /PRNewswire/ -- In collaboration with Saladax Biomedical, Inc., the Central European Society for Anticancer Drug Research (CESAR) announced today that enrollment has begun in the CEPAC-TDM trial of paclitaxel therapeutic drug management (TDM) with subsequent pharmacokinetic-guided dose adjustment in patients being treated for advanced non-small cell lung cancer (NSCLC).  The study will determine if optimizing dosing of paclitaxel will reduce grade 4 neutropenia, without affecting progression-free survival and overall survival.  Saladax is developing a nanoparticle-based automated immunoassay to provide rapid, simple and cost-effective measurement of paclitaxel levels to allow timely personalized dose adjustment.

This multicenter randomized trial is planned to enroll 280 patients.  In the first phase of the study, eight study centers will participate in Germany and Switzerland, with the first three patients already enrolled in Lowenstein, Germany.  The study is sponsored by CESAR and supported by Saladax Biomedical.

The CEPAC-TDM study is the first large scale, randomized trial to evaluate the clinical utility of paclitaxel drug dose management and is the largest randomized trial of its type.  A dosing algorithm has been derived that uses 24-hour paclitaxel plasma concentration and clinical parameters, based on a large population model of paclitaxel. In addition to the clinical results, extensive data on health economic outcomes will be generated through the trial.

Markus Joerger, MD PhD, explains: "The CEPAC-TDM clinical trial has the potential to markedly improve patient quality of life through a reduction of febrile neutropenia and hospitalization, and debilitating neuropathy, as it tailors paclitaxel to the individual patient's drug metabolism."

Study details

The CEPAC-TDM study is a phase III open-label, randomized, parallel-group clinical trial comparing conventional dosing of paclitaxel at 200 mg/m2 every three weeks (conventional treatment Arm A) with paclitaxel blood level testing and subsequent individual dose adjustments (experimental treatment Arm B), with the primary objective to significantly reduce grade 4 neutropenia in patients within treatment Arm B, without adversely affecting chemotherapy efficacy in terms of progression-free survival (PFS) and overall survival (OS).

About non-small cell lung cancer (NSCLC)

Lung cancer is the most common cancer in the world today, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all cases.  According to the Centers for Disease Control and Prevention (CDC), about 90% of lung cancer deaths in men and almost 80% of lung cancer deaths in women are due to smoking.  Treatment for NSCLC varies depending on the stage of the cancer, though combinations of taxanes are routinely used as part of first-line therapy treatment regimens.  Common side effects of taxanes include polyneuropathy and bone marrow suppression which results in severe neutropenia.

About pharmacokinetic-guided dosing

There is increasing evidence for the relationship between paclitaxel plasma concentrations, drug-associated toxicity, especially neutropenia and clinical outcome.  These data are derived from various pharmacological studies in patients with solid tumors, including lung cancer, ovarian cancer, breast cancer and less frequent cancer types.  The aim of TDM is to decrease toxicity while maintaining or improving treatment efficacy as compared to the standard of care.  Prospective pharmacokinetic studies with dose adjustments are important to evaluate the value of paclitaxel TDM.

About the CESAR Central European Society for Anticancer Drug Research-EWIV  

In the context of the pan-European Early Drug Development Network, CESAR represents the Central European platform for new development of novel drugs and therapies in oncology.  The scientific activity in the Working Groups encompasses the development of active substances (AWO), pharmacokinetic studies (APOH) and clinical studies in Phase I, II and III.  CESAR fosters cooperation with academic study groups, individual institutions in oncology and the pharmaceutical industry.  The CESAR Central Office (CCO) in Vienna offers the appropriate infrastructure for all phases of clinical trials, ranging from planning and implementation to project management, clinical documentation and statistical analyses.  CESAR, as a European Economic Interest Grouping (EEIG), is the umbrella organization of the registered societies CESAR Germany  and CESAR Austria  (with members from Austria and Switzerland).

About Saladax Biomedical, Inc.

Saladax Biomedical develops and commercializes novel diagnostic assays to achieve the promise of personalized medicine through dose management and companion diagnostic products for existing and new therapeutics.  Founded in 2004 and based in Bethlehem, PA, the company's dose management technology enables physicians to optimize the dose of drugs to meet individual patient needs, thus leading to improved response and better quality of life.  The Company's portfolio of 15 MyCare™ dose management assays is comprised of proprietary, automated and cost-effective in vitro diagnostic tests in various stages of development, with a principal focus in the field of oncology.  The first MyCare assay available to the oncology community is for one of the most common anticancer drugs, 5-fluorouracil, commonly referred to as 5-FU.  This assay is available in the United States from Myriad Genetics under the trade name OnDose™, sold by Saladax in Europe with CE Mark clearance as My5-FU® and will be distributed in Japan exclusively by FALCO biosystems.  Saladax also works with pharmaceutical companies to develop companion diagnostics to provide important clinical information to assist in the development and administration of new and existing compounds.  The Company has entered into a multi-year development and commercialization agreement with Bristol-Myers Squibb Company (NYSE: BMY) for the development of certain clinical diagnostic tests to be used in conjunction with the development of certain therapeutic compounds in the BMS pipeline.

My5-FU is a registered trademark of Saladax Biomedical, Inc.

OnDose is a trademark of Myriad Genetics, Inc.  

CESAR Central European Society for Anticancer Drug Research – EWIV

Berta Moritz, PhD
Director, Clinical Affairs
berta.moritz@cesar.or.at
www.cesar.or.at

Saladax Biomedical, Inc.
Adrienne Choma, Esq.
VP, Marketing & Sales
achoma@saladax.com

Saladax Media Contact
Tiberend Strategic Advisors, Inc.
+1-212-827-0020
Farrell Denby
fdenby@tiberend.com
or
Andrew Mielach
amielach@tiberend.com


'/>"/>
SOURCE Saladax Biomedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Symmetry Medical Centralizes Businesses Under CEO
2. Central Texas Hospital Selects eCareSoft EHR Technology
3. FDA Approves Gadavist for Central Nervous System Scans
4. U.S. FDA Approves Bayers Gadavist™ (Gadobutrol) Injection for MRI of the Central Nervous System
5. Mithridion, Inc. Announces New Funding and Outlines Strategy for Central Nervous System Drug Development
6. Reportlinker Adds The Outlook for Pharmaceuticals in Central Asia
7. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
8. Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME)
9. Cipher Pharmaceuticals Using MedAvante Centralized Ratings in Phase 3 Study
10. Rexahn to Use MedAvante Centralized Ratings in MDD Phase 2b Study
11. Wound Management Technologies Adds Panama to Growing List of Distribution Points in Central America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec. 8, 2016 Allergy Diagnostics Market: ... and tests that are used to determine the ... milk, or drugs etc. in the samples by ... immune system. The report on global allergy diagnostics ... the market. The report consists of an executive ...
(Date:12/8/2016)... Markets has announced the addition of the "Endodontic Supplies - Global Strategic ... , ... for Endodontic Supplies in US$ Thousand. The report provides separate comprehensive analytics for ... Europe , Asia-Pacific , Latin America ... provided for the period 2015 through 2022. Also, a six-year historic analysis is ...
(Date:12/8/2016)... 2016  A Mederi Therapeutics Inc . anunciou aprovação regulatória, pela CFDA, ... a doença do refluxo gastroesofágico (DRGE). Foto -  http://photos.prnewswire.com/prnh/20161207/446903 ... ... Live Stretta procedure performed and broadcast during the Chinese Congress of Digestive ... , , ...
Breaking Medicine Technology:
(Date:12/8/2016)... , ... December 08, 2016 , ... ... become Quality Insights beginning January 1, 2017. The name change aligns the ... to measuring and improving health care quality. , “We are very proud of ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Medication Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced ... counsel and Eric Hoessel to vice president of sales. , Litsinger joined ...
(Date:12/8/2016)... , ... December 08, 2016 , ... David J. ... global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, ... the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical Technology ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... version gives development continuity to its innovative Unified Instance Manager architecture, meeting ... In addition, this new version optimizes the unattended auto-dialing system without agents, ...
Breaking Medicine News(10 mins):